Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 24 peer-reviewed journal articles Updated
Medical Genetics

The Biology of Gorlin Syndrome: Broken Brakes and Cell Growth

At a Glance

Gorlin syndrome is caused by genetic mutations, usually in the PTCH1 or SUFU genes, that prevent the body from controlling cell growth properly. Knowing your specific gene mutation is essential because it determines your specific risks for skin cancers, jaw cysts, and childhood brain tumors.

To understand Gorlin syndrome, it helps to think of your body as a high-performance car. Your cells are constantly “driving” to grow and repair tissue. In a healthy car, the Hedgehog signaling pathway acts as the engine’s control system, telling the car when to speed up growth and when to hit the brakes [1][2].

In Gorlin syndrome, one of the “brake” systems is broken. This leads to the constitutive activation (the pathway stays “on” all the time) of cell growth, which can result in the various features of the syndrome, such as skin lesions or cysts [3][4].

The Role of PTCH1 and SUFU

Most people with Gorlin syndrome have a mutation in one of two primary genes that act as these biological brakes:

  • PTCH1 (The Primary Brake): About 85-90% of people with Gorlin syndrome have a mutation in the PTCH1 gene [5][6]. This gene sits on the surface of the cell and usually keeps another protein, called Smoothened (SMO), from starting the growth engine [1][2]. When PTCH1 is broken, SMO is free to signal the cell to grow uncontrollably [2][7].
  • SUFU (The Backup Brake): The SUFU gene works deeper inside the cell. It grabs onto the “accelerators” (called GLI proteins) and keeps them from entering the cell’s command center (the nucleus) [8][9].

Why Your Specific Gene Matters

Knowing which gene is mutated is vital because it changes the “risk profile” for different health issues. Your screening and surveillance will look very different based on this result:

Feature PTCH1 Mutation SUFU Mutation
Basal Cell Carcinomas (BCCs) Very Common [10] Less Common [10]
Jaw Cysts (OKCs) Very Common [10] Rare [11]
Medulloblastoma (Brain Tumor) Low Risk (<2%) [12] High Risk (~33%) [13][14]

Because children with a SUFU mutation have a much higher risk of medulloblastoma, they require aggressive and frequent brain imaging (such as an MRI every 4 months) from birth until age 5 [15][16].

Emerging Genes: ELP1

Recently, researchers have identified the ELP1 gene as another factor [17]. Mutations in ELP1 are primarily linked to a specific type of medulloblastoma in children [18][19]. While it doesn’t always cause the full “classic” Gorlin syndrome appearance, it is now part of the conversation for families managing these risks [17][20].

How Gorlin Syndrome is Inherited

Gorlin syndrome follows an autosomal dominant inheritance pattern [21][4]. This means:

  • 50% Chance: If a parent has the syndrome, there is a 50% chance they will pass the mutated gene to each child [21].
  • De Novo Mutations: About 35-50% of the time, the mutation is “de novo”—it is brand new in that person, and neither parent has the condition [22].
  • No “Skipping” Generations: The gene doesn’t hide; if you have the mutation, you have the syndrome, though symptoms can vary wildly even within the same family [21][23].

Understanding these biological “brakes” is the first step toward effective management. It explains why certain systemic treatments (like Hedgehog inhibitors) work by manually trying to turn off the engine that the broken brakes couldn’t stop [21][24].

Common questions in this guide

What is the difference between a PTCH1 and SUFU mutation?
Both genes normally act as brakes on cell growth, but mutations in them lead to different risks. A PTCH1 mutation commonly causes skin cancers and jaw cysts, while a SUFU mutation significantly increases the risk of childhood brain tumors.
What are the chances of passing Gorlin syndrome to my child?
Because it is an autosomal dominant condition, a parent with Gorlin syndrome has a 50 percent chance of passing the mutated gene to each of their children. The gene does not skip generations.
Can I have Gorlin syndrome if no one else in my family does?
Yes, this happens frequently. In about 35 to 50 percent of cases, the gene mutation is brand new in the affected person and was not inherited from either parent. This is known as a de novo mutation.
Why might my child need frequent brain MRI scans?
Children with certain genetic findings, particularly a SUFU mutation, have a highly elevated risk of developing a brain tumor called medulloblastoma. Frequent MRI scans are crucial to monitor this risk safely from birth until age five.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Does my genetic test result show a mutation in the PTCH1, SUFU, or ELP1 gene?
  2. 2.Based on my specific gene mutation, what is my child's (or my) lifetime risk of medulloblastoma?
  3. 3.How often should we be doing brain MRI scans based on this specific genetic finding, and at what age can we stop?
  4. 4.Since this is an autosomal dominant condition, which of my family members should be tested?
  5. 5.If no one else in my family has this, was this a 'de novo' (brand-new) mutation?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (24)
  1. 1

    Novel PTCH1 mutations in Japanese familial nevoid basal cell carcinoma syndrome.

    Nakase Y, Hamada A, Kitamura N, et al.

    Human genome variation 2020; (7(1)):38 doi:10.1038/s41439-020-00126-6.

    PMID: 33298892
  2. 2

    Novel clinical and molecular findings in Spanish patients with naevoid basal cell carcinoma syndrome.

    Alonso N, Cañueto J, Ciria S, et al.

    The British journal of dermatology 2018; (178(1)):198-206 doi:10.1111/bjd.15835.

    PMID: 28733979
  3. 3

    Whole-exome sequencing of nevoid basal cell carcinoma syndrome families and review of Human Gene Mutation Database PTCH1 mutation data.

    Gianferante DM, Rotunno M, Dean M, et al.

    Molecular genetics & genomic medicine 2018; (6(6)):1168-1180 doi:10.1002/mgg3.498.

    PMID: 30411536
  4. 4

    Genomic profiling of late-onset basal cell carcinomas from two brothers with nevoid basal cell carcinoma syndrome.

    Hasan Ali O, Yurchenko AA, Pavlova O, et al.

    Journal of the European Academy of Dermatology and Venereology : JEADV 2021; (35(2)):396-402 doi:10.1111/jdv.16767.

    PMID: 32564428
  5. 5

    Ocular manifestations in Gorlin-Goltz syndrome.

    Moramarco A, Himmelblau E, Miraglia E, et al.

    Orphanet journal of rare diseases 2019; (14(1)):218 doi:10.1186/s13023-019-1190-6.

    PMID: 31533758
  6. 6

    Further Expanding the Mutational Spectrum of Gorlin Syndrome in Three Unrelated Families.

    Kolkiran A, Şimşek-Kiper PÖ, Topaloğlu Yasan G, et al.

    Molecular syndromology 2024; (15(3)):175-184 doi:10.1159/000535407.

    PMID: 38841331
  7. 7

    Basal cell carcinomas acquire secondary mutations to overcome dormancy and progress from microscopic to macroscopic disease.

    Trieu KG, Tsai SY, Eberl M, et al.

    Cell reports 2022; (39(5)):110779 doi:10.1016/j.celrep.2022.110779.

    PMID: 35508126
  8. 8

    The role of the Hedgehog signaling pathway in cancer: A comprehensive review.

    Skoda AM, Simovic D, Karin V, et al.

    Bosnian journal of basic medical sciences 2018; (18(1)):8-20 doi:10.17305/bjbms.2018.2756.

    PMID: 29274272
  9. 9

    Hedgehog/GLI Signaling Pathway: Transduction, Regulation, and Implications for Disease.

    Sigafoos AN, Paradise BD, Fernandez-Zapico ME

    Cancers 2021; (13(14)) doi:10.3390/cancers13143410.

    PMID: 34298625
  10. 10

    Germline SUFU mutation carriers and medulloblastoma: clinical characteristics, cancer risk, and prognosis.

    Guerrini-Rousseau L, Dufour C, Varlet P, et al.

    Neuro-oncology 2018; (20(8)):1122-1132 doi:10.1093/neuonc/nox228.

    PMID: 29186568
  11. 11

    First evidence of genotype-phenotype correlations in Gorlin syndrome.

    Evans DG, Oudit D, Smith MJ, et al.

    Journal of medical genetics 2017; (54(8)):530-536 doi:10.1136/jmedgenet-2017-104669.

    PMID: 28596197
  12. 12

    Gorlin-like phenotype in a patient with a PTCH2 variant of uncertain significance.

    Casano K, Meddaugh H, Zambrano RM, et al.

    European journal of medical genetics 2020; (63(4)):103842 doi:10.1016/j.ejmg.2020.103842.

    PMID: 31945512
  13. 13

    The relevance of a suppressor of fused (SUFU) mutation in the diagnosis and treatment of Gorlin syndrome.

    Ogden T, Higgins S, Elbaum D, Wysong A

    JAAD case reports 2018; (4(2)):196-199 doi:10.1016/j.jdcr.2017.10.011.

    PMID: 29892665
  14. 14

    Basaloid follicular proliferations, brain tumours and SUFU.

    Manam S, Oliphant T, Husain A, Rajan N

    The British journal of dermatology 2020; (183(5)):e146 doi:10.1111/bjd.19248.

    PMID: 32588433
  15. 15

    Current recommendations for cancer surveillance in Gorlin syndrome: a report from the SIOPE host genome working group (SIOPE HGWG).

    Guerrini-Rousseau L, Smith MJ, Kratz CP, et al.

    Familial cancer 2021; (20(4)):317-325 doi:10.1007/s10689-021-00247-z.

    PMID: 33860896
  16. 16

    Cancer Surveillance in Gorlin Syndrome and Rhabdoid Tumor Predisposition Syndrome.

    Foulkes WD, Kamihara J, Evans DGR, et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2017; (23(12)):e62-e67 doi:10.1158/1078-0432.CCR-17-0595.

    PMID: 28620006
  17. 17

    Exploration of the causative gene in a case of multiple nevoid basal cell carcinoma: A case report.

    Liu Y, Gao X, Cao L, et al.

    Rare tumors 2024; (16()):20363613241290394 doi:10.1177/20363613241290394.

    PMID: 39399445
  18. 18

    Germline Elongator mutations in Sonic Hedgehog medulloblastoma.

    Waszak SM, Robinson GW, Gudenas BL, et al.

    Nature 2020; (580(7803)):396-401 doi:10.1038/s41586-020-2164-5.

    PMID: 32296180
  19. 19

    A novel ELP1 mutation impairs the function of the Elongator complex and causes a severe neurodevelopmental phenotype.

    Kojic M, Abbassi NEH, Lin TY, et al.

    Journal of human genetics 2023; (68(7)):445-453 doi:10.1038/s10038-023-01135-3.

    PMID: 36864284
  20. 20

    Basal cell nevus syndrome: an update on clinical findings.

    Fernández LT, Ocampo-Garza SS, Elizondo-Riojas G, Ocampo-Candiani J

    International journal of dermatology 2022; (61(9)):1047-1055 doi:10.1111/ijd.15884.

    PMID: 34494262
  21. 21

    A Rare Case of Gorlin-Goltz Syndrome in Children.

    Boos Lima FBDJ, Viana APC, Lima LHF, et al.

    Case reports in dentistry 2019; (2019()):1608783 doi:10.1155/2019/1608783.

    PMID: 31934460
  22. 22

    Gorlin-Goltz syndrome with familial manifestation.

    Pazdera J, Santava A, Kolar Z

    Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia 2022; (166(1)):112-116 doi:10.5507/bp.2020.063.

    PMID: 33542540
  23. 23

    Genetic aspects of Gorlin‒Goltz syndrome

    Vetró É, Oláh J, Nagy D, et al.

    Orvosi hetilap 2020; (161(49)):2072-2077 doi:10.1556/650.2020.31933.

    PMID: 33279882
  24. 24

    Gorlin Syndrome-Associated Basal Cell Carcinomas Treated with Vismodegib or Sonidegib: A Retrospective Study.

    Murgia G, Valtellini L, Denaro N, et al.

    Cancers 2024; (16(12)) doi:10.3390/cancers16122166.

    PMID: 38927872

This page provides an educational overview of Gorlin syndrome genetics. Always consult a genetic counselor or your doctor to accurately interpret your genetic test results and determine the appropriate screening schedule.

Get notified when new evidence is published on Gorlin syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.